1. Home
  2. CYPH vs IBIO Comparison

CYPH vs IBIO Comparison

Compare CYPH & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CYPH

Cypherpunk Technologies Inc.

N/A

Current Price

$0.75

Market Cap

73.4M

Sector

Health Care

ML Signal

N/A

Logo iBio Inc.

IBIO

iBio Inc.

HOLD

Current Price

$1.64

Market Cap

84.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYPH
IBIO
Founded
2011
2008
Country
United States
United States
Employees
6
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.4M
84.0M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
CYPH
IBIO
Price
$0.75
$1.64
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$4.75
AVG Volume (30 Days)
6.8M
781.0K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
73.08
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.49
$0.56
52 Week High
$3.70
$3.82

Technical Indicators

Market Signals
Indicator
CYPH
IBIO
Relative Strength Index (RSI) 43.75 44.23
Support Level $0.54 $1.41
Resistance Level $0.79 $1.80
Average True Range (ATR) 0.11 0.15
MACD -0.02 -0.02
Stochastic Oscillator 31.82 26.23

Price Performance

Historical Comparison
CYPH
IBIO

About CYPH Cypherpunk Technologies Inc.

Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.

About IBIO iBio Inc.

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

Share on Social Networks: